Document is current
Any future updates will be listed below
-
Authors
Yachida, Shinichi https://orcid.org/0000-0001-5507-4566
Mizutani, Sayaka https://orcid.org/0000-0003-4168-6195
Shiroma, Hirotsugu
Shiba, Satoshi
Nakajima, Takeshi
Sakamoto, Taku
Watanabe, Hikaru
Masuda, Keigo
Nishimoto, Yuichiro
Kubo, Masaru
Hosoda, Fumie
Rokutan, Hirofumi
Matsumoto, Minori
Takamaru, Hiroyuki
Yamada, Masayoshi
Matsuda, Takahisa https://orcid.org/0000-0002-9244-2820
Iwasaki, Motoki
Yamaji, Taiki
Yachida, Tatsuo
Soga, Tomoyoshi
Kurokawa, Ken https://orcid.org/0000-0001-8662-9958
Toyoda, Atsushi https://orcid.org/0000-0002-0728-7548
Ogura, Yoshitoshi
Hayashi, Tetsuya
Hatakeyama, Masanori
Nakagama, Hitoshi
Saito, Yutaka
Fukuda, Shinji
Shibata, Tatsuhiro
Yamada, Takuji https://orcid.org/0000-0002-9622-1849
- License Information
-
More Information
Article History
Received: 10 September 2018
Accepted: 11 April 2019
First Online: 6 June 2019
Competing interests
: S.F. and T. Yamada are founders of Metabologenomics. The company is focused on the design and control of the gut environment for human health. The company had no control over the interpretation, writing or publication of this work. The terms of these arrangements are being managed by Keio University and Tokyo Institute of Technology in accordance with its conflict of interest policies. S.Y., S.F. and T. Yamada are currently applying for a patent (2018–18134/PCT/JP2019/3825, ‘Method for diagnosing the early stage of colorectal cancers based on the gut microbiome and metabolome profiles’).
